Search research articles
Contact Us
Filters
Showing results (1-10 of 345) with videos related to
Page
of 35
Sort By:
Current Rheumatology Reports
|
October 5, 2007
Malignancy and rheumatoid arthritis
Johan Askling
Rheumatology (Oxford, England)
|
May 7, 2019
Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply
Thomas Frisell, Johan Askling
Annals of the Rheumatic Diseases
|
March 5, 2011
Influence of biological agents on cardiovascular disease in rheumatoid arthritis
Johan Askling, Will Dixon
Current Opinion in Rheumatology
|
March 20, 2008
The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis
Johan Askling, Will Dixon
Annals of the Rheumatic Diseases
|
February 2, 2021
Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervou <i>et al</i>
Viktor Molander, Johan Askling
Annals of the Rheumatic Diseases
|
March 19, 2014
Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al
Martin Neovius, Johan Askling
Current Opinion in Rheumatology
|
April 5, 2008
Malignancy and biologic therapy in rheumatoid arthritis
Johan Askling, Tim Bongartz
Rheumatology (Oxford, England)
|
March 7, 2019
Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply
Thomas Frisell, Johan Askling
Annals of the Rheumatic Diseases
|
June 21, 2015
Does a family history of RA influence the clinical presentation and treatment response in RA?
Thomas Frisell, Saedis Saevarsdottir, Johan Askling
Nature Reviews. Rheumatology
|
April 22, 2016
Family history of rheumatoid arthritis: an old concept with new developments
Thomas Frisell, Saedis Saevarsdottir, Johan Askling
Page
of 35
Search research articles
Search
Showing results (1-10 of 345) with videos related to
Sort By:
Page
of 35
Current Rheumatology Reports
|
October 5, 2007
Malignancy and rheumatoid arthritis
Johan Askling
Rheumatology (Oxford, England)
|
May 7, 2019
Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply
Thomas Frisell, Johan Askling
Annals of the Rheumatic Diseases
|
March 5, 2011
Influence of biological agents on cardiovascular disease in rheumatoid arthritis
Johan Askling, Will Dixon
Current Opinion in Rheumatology
|
March 20, 2008
The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis
Johan Askling, Will Dixon
Annals of the Rheumatic Diseases
|
February 2, 2021
Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervou <i>et al</i>
Viktor Molander, Johan Askling
Annals of the Rheumatic Diseases
|
March 19, 2014
Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al
Martin Neovius, Johan Askling
Current Opinion in Rheumatology
|
April 5, 2008
Malignancy and biologic therapy in rheumatoid arthritis
Johan Askling, Tim Bongartz
Rheumatology (Oxford, England)
|
March 7, 2019
Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply
Thomas Frisell, Johan Askling
Annals of the Rheumatic Diseases
|
June 21, 2015
Does a family history of RA influence the clinical presentation and treatment response in RA?
Thomas Frisell, Saedis Saevarsdottir, Johan Askling
Nature Reviews. Rheumatology
|
April 22, 2016
Family history of rheumatoid arthritis: an old concept with new developments
Thomas Frisell, Saedis Saevarsdottir, Johan Askling
Page
of 35